Company intelligence / Profile preview

Kelun-Biotech

Chengdu, Sichuan, Chinaen.kelun-biotech.com ↗
Ownership
Public · 6990
Development stage
Commercial
01

Overview

Kelun-Biotech has built a robust pipeline of over thirty assets—including more than ten clinical-stage programs—focused on innovative biologics and small molecules for oncology and other major diseases. Its proprietary OptiDC™ ADC platform underpins several first-in-class or best-in-class candidates. Fourteen programs are in clinical development in China; two have entered US trials. Notable recent progress includes FDA IND clearance for SKB518 ADC targeting advanced solid tumors.[10] The company has established global partnerships validating its technology.[5]

Therapeutic areas
OncologyMetabolic DisordersImmunologyInfectious Diseases
Modalities
Antibody-drug conjugates (ADCs)Monoclonal antibodies (mAbs)Bispecific antibodies (bsAbs)Small molecules
Industry
Biotech
02

Drug pipeline

34 assets

KL-140

4

33 more assets in the full pipeline.

Request access →
03

Partnerships

Merck & Co., Inc.: Exclusive license/collaboration agreement covering multiple investigational preclinical/clinical antibody-drug conjugate therapies for cancer treatment worldwide except Greater China region.Harbour BioMed Therapeutics LimitedWindward Bio AGEllipses Pharma Limited

Beyond the preview

Go deeper on Kelun-Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Full profile access

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Full profile access

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Full profile access

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Full profile access

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Full profile access

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kelun-Biotech.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call